Gastrointestinal Cancer News

Adding regorafenib to best supportive care significantly increased survival rates compared with placebo among patients with refractory advanced gastroesophageal cancer, results of the randomized, phase 3 INTEGRATE IIa trial showed.

The FDA granted accelerated approval to tucatinib in combination with trastuzumab for adults with RAS wild-type, HER2-positive metastatic or unresectable colorectal cancer, according to a company press release.

Adjuvant therapy with atezolizumab and bevacizumab reduced recurrence risk compared with active surveillance for patients with certain types of early-stage liver cancer, according to topline data released by the agents’ manufacturer.

In a scientific statement, the American Heart Association issued guidance on the epidemiology, diagnosis and management of cancer therapy-induced hypertension.

Excess weight, regardless of polygenic risk score, correlated with an increased risk for colorectal cancer, according to results from a population-based, case-control study.

Patients who have been diagnosed with cancer value interventions that address their mental and emotional well-being, according to results of a survey study.

Futibatinib demonstrated clinical benefit among previously treated patients with fibroblast growth factor receptor 2 fusion- or rearrangement-positive intrahepatic cholangiocarcinoma, according to results of a phase 2 study.

Researchers reported low prevalence for advanced colorectal neoplasms at screening colonoscopies conducted at least 10 years after a negative index colonoscopy, especially among women younger than 75 years.

Researchers have proposed a machine-learning algorithm for personalized treatment selection in patients with recurrent hepatocellular carcinoma, based on data published in JAMA Surgery.

Black and Hispanic patients with cancer and caregivers appeared more likely than their white counterparts to report at least one negative care experience, according to study results.